anti-b7-h3 antibody-drug conjugate db-1311
anti-b7-h3 antibody-drug conjugate db-1311: 3 clinical trials tracked.
anti-b7-h3 antibody-drug conjugate db-1311 evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
What is verified about anti-b7-h3 antibody-drug conjugate db-1311, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (3)
A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer
Primary endpoint: rPFS assessed by BICR
A Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327 in Participants With Advanced Lung Cancer
Primary endpoint: Part 1 - Occurrence of dose limiting toxicities (DLTs) by dose level
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors
Primary endpoint: Phase 1: Percentage of Participants with Dose-Limiting Toxicities (DLTs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Percentage of participants in Part 1 with DLTs